The Conversation (0)
X8bCVDzJj1rLNPSToQzynb3ArXuLc89KvwqfeOy5zlJdWNTDjTpHnpTqCtXDWjR82gJDpl9ANGdZUbObz8FKxoTyyZSHQrE2CKdt-tGIlT3qvNrBKOnNxq4Gndg0G4a4eAv--5oZfePwuWEJXxLyYz6xKthbsY5ScwERZTxW8IkJ3elolvTOxkjnfLbkBHd5JbXIip5FLq-h8a4QRXoG8TAJfQP1qD6SjwqZLuXy52otnMM2z0CYNG3YF_s6ZyIGoO7CbVNmG6b" target="_blank" rel="nofollow">Xd3Gif2UrgBUWUgH70d8log7_tG4Tndg0LFn4zePl3XyJtA432rfstf9OBrkCvqXSPM4bosA9dICAAEKcqMGIyzF2Oy6tRTTws5UrXqOQjNNcKhVuJBLZYKgze8cjlvVPNkR3WqLpeiIrpq2x9vpkVWVA6LiMc8W1mWez8BrfXBDyqdSaRlf1gUKJq5UeLGBPgqwxNwxlc8JbN0tXuBj03MYGl9wYyDGPxZrcM4zwqoKY_mx7__pfc90RrTkQ" target="_blank" rel="nofollow">Cullinan Therapeutics, Inc. (Nasdaq: CGEM; "Cullinan"), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 1:30 p.m. ET.
A webcast of the fireside chat will be available under the Events and Presentations section of the Company's investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
Contacts:
Investors
Nick Smith
+1 401.241.3516
Nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
Rweldon@cullinantx.com
